Real-world outcomes (RWO) with tandem transplantation in patients (pts) with newly diagnosed multiple myeloma (NDMM).
Effect of maintenance therapy (MT) on real-world outcomes (RWO) of patients (pts) with newly diagnosed multiple myeloma (NDMM) post stem cell transplant (SCT).
Assessment of algorithms for identifying patients with triple-class refractory multiple myeloma using real-world data
Real-world comparison of daratumumab-based regimens in relapsed/refractory multiple myeloma using health record data
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms intriple-class refractory multiple myeloma
An Indirect Comparison of Elranatamab’s Progression-Free Survival and Overall Survival from Magnetismm-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma
Clinical Outcomes in Real-World Patients (RW) with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): A Retrospective Study Using Electronic Health Records from Flatiron Health and COTA Vantage Databases
An indirect comparison of elranatamab’s (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM)
Patient- and Clinician-Reported Performance Status in Patients with Multiple Myeloma Treated in the United States Using Real World Data
Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified By Exposure to Lenalidomide or Anti-CD38 Therapy and Double-Class Refractory Status: A Retrospective Electronic Health Record Database Study
